Literature DB >> 21149896

mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.

Józefa Wesierska-Gadek1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21149896      PMCID: PMC3034175          DOI: 10.18632/aging.100240

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


× No keyword cloud information.
The limited dividing potential of normal cells leads to replicative cellular senescence that is defined by irreversible loss of proliferative potential, adoption of characteristic morphology and expression of typical biomarkers [1,2]. Cellular senescence acts as a barrier to malignant cell transformation in vivo [3] and may contribute to organismal ageing [1,2,4]. The p53 tumor suppressor is a major determinant of cellular senescence [5]. It plays a crucial role in the integration of stress signaling and coordination of cellular responses to stress. Depending on the kind of stress stimuli, stress strength and cellular context, activation of tumor suppressor p53 can induce reversible quiescence, cellular senescence and apoptosis [6]. The function of wt p53 is extremely complex and, of course, has to be explained within the context of the expression of distinct p53 isoforms, levels of p53-induced micro-RNA and a complex network of p53-interacting proteins. Two p53 isoforms (Δ133p53 and p53β), and in particular their mutual interaction, seem to act as endogenous regulators of cellular senescence in normal human fibroblasts [7]. The relevance of these findings to in vivo events reflects the fact that increases in Δ133p53 expression and reductions in p53β expression have been observed in vivo in colon adenomas with senescent phenotypes [8]. The cancer-protective function of wt p53 is also related to its master function in the regulation of various stages of apoptosis [9]. However, wt p53 plays a dual role in the control of cells' suicide; depending on stress strength it can either prevent or induce programmed cell death. While the apoptosis-promoting function of p53tumor suppressor protein has been intensively scrutinized and is indisputable, the pro-survival function of wt p53 (mediated inter alia via TIGAR, its downstream target) has been less explored and due to some controversies remains an object of debate. However, p53 tumor suppressor has been shown to respond to metabolic changes and to influence metabolic pathways through several mechanisms. In response to a lack of nutrients, p53 becomes activated through the activation of AMP-activated protein kinase (AMPK) and the inhibition of AKT. p53 protein further induces AMPK (both directly and indirectly through the sestrins) and activates the expression of tuberous sclerosis 2 (TSC2), resulting in the inhibition of mTOR, a cytoplamic kinase that transfers signals induced by growth factors to cellular machinery promoting cell proliferation and survival. However, cross-talk between p53 and the mTOR signaling pathways is more complex. Recent studies provide evidence regarding the decision-making role of these pathways in the choice between p53-mediated cellular quiescence and senescence. The paradoxical function of p53, on the one hand repressing cellular senescence by promoting quiescence, and on the other inducing senescence, has been systematically addressed and rigorously studied by M. Blagosklonny and colleagues [10-11]. Demidenko et al. [10] have shown that suppression of cellular senescence by wt p53 is associated with p53-induced quiescence and requires p53 transactivation and inhibition of mTOR. Conversely, the activation of mTOR by depletion of TSC2, a negative regulator of mTOR, favors senescence in normal cells [11]. These observations seem to explain why limited activation of p53 may prolong the lifespan of mice [12] and correlate with observations of age-related decline in p53 function. In this issue, Leontieva and Blagosklonny further explore the crosstalk between p53 and mTOR in normal cells and highlight the role of the functional status of mTOR in the transition of cells from quiescence to senescence [13]. To separate these activities the authors induced quiescence prior to the induction of p53, using either the DNA-damaging drug etoposide or nutlin-3a, which induces Mdm2-mediated degradation but does not damage DNA. After removal of nutlin-3a and serum refeeding, nutlin-3a-treated cells entered the cell cycle and divided, whereas etoposide-treated cells did not proliferate after etoposide removal and serum addition. However, etoposide-treated cells re-entered cell cycling if co-treated with rapamycin, implying that functional mTOR is essential for permanent loss of proliferative potential. Thus, this study provides evidence that activation of mTOR in quiescent cells is a decision-making factor in the transition to cellular senescence.
  12 in total

1.  Paradoxical suppression of cellular senescence by p53.

Authors:  Zoya N Demidenko; Lioubov G Korotchkina; Andrei V Gudkov; Mikhail V Blagosklonny
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

3.  p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation.

Authors:  C Y Dai; E E Furth; R Mick; J Koh; T Takayama; Y Niitsu; G H Enders
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

4.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints.

Authors:  Jirina Bartkova; Nousin Rezaei; Michalis Liontos; Panagiotis Karakaidos; Dimitris Kletsas; Natalia Issaeva; Leandros-Vassilios F Vassiliou; Evangelos Kolettas; Katerina Niforou; Vassilis C Zoumpourlis; Munenori Takaoka; Hiroshi Nakagawa; Frederic Tort; Kasper Fugger; Fredrik Johansson; Maxwell Sehested; Claus L Andersen; Lars Dyrskjot; Torben Ørntoft; Jiri Lukas; Christos Kittas; Thomas Helleday; Thanos D Halazonetis; Jiri Bartek; Vassilis G Gorgoulis
Journal:  Nature       Date:  2006-11-30       Impact factor: 49.962

5.  p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence.

Authors:  Kaori Fujita; Abdul M Mondal; Izumi Horikawa; Giang H Nguyen; Kensuke Kumamoto; Jane J Sohn; Elise D Bowman; Ewy A Mathe; Aaron J Schetter; Sharon R Pine; Helen Ji; Borivoj Vojtesek; Jean-Christophe Bourdon; David P Lane; Curtis C Harris
Journal:  Nat Cell Biol       Date:  2009-08-23       Impact factor: 28.824

Review 6.  p53 and metabolism.

Authors:  Karen H Vousden; Kevin M Ryan
Journal:  Nat Rev Cancer       Date:  2009-09-17       Impact factor: 60.716

Review 7.  The tumor suppressor p53: cancer and aging.

Authors:  Zhaohui Feng; Wenwei Hu; Gunaretnam Rajagopal; Arnold J Levine
Journal:  Cell Cycle       Date:  2008-01-23       Impact factor: 4.534

Review 8.  An oncogene-induced DNA damage model for cancer development.

Authors:  Thanos D Halazonetis; Vassilis G Gorgoulis; Jiri Bartek
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

9.  The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.

Authors:  Lioubov G Korotchkina; Olga V Leontieva; Elena I Bukreeva; Zoya N Demidenko; Andrei V Gudkov; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2010-06       Impact factor: 5.682

10.  DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.

Authors:  Olga V Leontieva; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2010-12       Impact factor: 5.682

View more
  15 in total

Review 1.  Rapalogs in cancer prevention: anti-aging or anticancer?

Authors:  Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2012-11-14       Impact factor: 4.742

Review 2.  Controversial aspects of oncogene-induced senescence.

Authors:  Anna Bianchi-Smiraglia; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

3.  p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.

Authors:  William H Chappell; Brian D Lehmann; David M Terrian; Stephen L Abrams; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2012-11-27       Impact factor: 4.534

4.  Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2012-06

Review 5.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

6.  Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.

Authors:  Olga V Leontieva; Geraldine M Paszkiewicz; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

Review 7.  Answering the ultimate question "what is the proximal cause of aging?".

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

8.  Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling.

Authors:  H Dorota Halicka; Hong Zhao; Jiangwei Li; Yong-Syu Lee; Tze-Chen Hsieh; Joseph M Wu; Zbigniew Darzynkiewicz
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

9.  Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2012-12

Review 10.  Advances in targeting signal transduction pathways.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Lin Sun; Nicole M Davis; Stephen L Abrams; Richard A Franklin; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli; Massimo Libra; Saverio Candido; Giovanni Ligresti; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Marco Donia; Ferdinando Nicoletti; Jerry Polesel; Renato Talamini; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Michele; Agostino Tafuri; Joanna Dulińska-Litewka; Piotr Laidler; Antonio B D'Assoro; Lyudmyla Drobot; Drobot Umezawa; Giuseppe Montalto; Melchiorre Cervello; Zoya N Demidenko
Journal:  Oncotarget       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.